Triple-Negative Breast Cancer Treatment Advancements: A Review of Evolving Strategies

Women around the world are most frequently afflicted with breast cancer, and it is one of the most frequent causes of cancer death in females. Breast cancer is usually classified according to biomarker status, triple‐negative breast cancer (TNBC) represents a distinct subtype characterized by immuno...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer care 2024-04, Vol.2024, p.1-12
Main Authors: Liu, Guozheng, Zhang, Yanwen, Huang, Yong
Format: Article
Language:English
Subjects:
Androgens
B cells
Biomarkers
Breast cancer
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Cytotoxicity
DNA repair
Drug dosages
Drug resistance
Drug therapy
Epidermal growth factor
ErbB-2 protein
Estrogen receptors
Estrogens
Growth factors
Immune system
Immunology
Immunotherapy
Lymphocytes
Medical prognosis
Medical research
Metastases
Metastasis
Mutation
Phenotypes
Progesterone
Radiation therapy
Receptors
Surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Women around the world are most frequently afflicted with breast cancer, and it is one of the most frequent causes of cancer death in females. Breast cancer is usually classified according to biomarker status, triple‐negative breast cancer (TNBC) represents a distinct subtype characterized by immunohistochemical findings that denote negativity for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her-2) on cancer tissue. It is more common in younger women than in other subtypes. As an invasive breast cancer subtype with a unique drug-resistant phenotype and metastatic burden, it has limited treatment options, and patients have a poor prognosis with high rates of local, distant recurrence and mortality, and there is still a lack of standardized treatment protocols for TNBC. In this review, we delve into the current treatment strategies for TNBC and explore the potential for new approaches and targets in the future. This trial is registered with NCT03997123.
ISSN:0961-5423
1365-2354
DOI:10.1155/2024/8299502